Strain ts-S34 of Bordetella bronchiseptica was treated jointly with two mutagens, nitrosoguanidine and UV irradiation, and a urease-negative (u-), temperature-sensitive (ts) mutant strain indistinguishable from Alcaligenes faecalis in its biochemical characteristics was isolated. However, the mutant isolated was a phase III organism. By repeating selection of smaller, hemolytic colonies observed among phase III colonies after prolonged incubation, a phase I organism, strain ts-S34 u-, was isolated. The u-and ts properties of the mutant strain were hereditarily stable, and heat-labile toxin production was very low. Growth in KCN broth and on Simmons citrate agar was reduced. Agglutinability of the strain against anti-Si and anti-ts-S34 u-hyperimmune sera was as high (x20,480) as that of wild-type strain S1. The live ts-S34 u-strain vaccination protected guinea pigs from challenge exposure with 15,000 x the 50% lethal dose of virulent strain S1 of B. bronchiseptica. In these studies, it appeared that the ts-S34 u-strain has favorable properties, including a useful hereditary marker and low heat-labile toxin production, for use as a live attenuated vaccine.
Bordetella bronchiseptica has been known to be an etiological agent of respiratory diseases of laboratory and domestic animals (9) . Among these respiratory diseases, swine infectious atrophic rhinitis is characterized by atrophy of nasal turbinates and growth retardation (3) . B. bronchiseptica-inoculated young pigs gained 26% less body weight than did controls, reduced feed efficiency 12% below the control rate, and had shrunken turbinates (2). Hanada et al. (3) reported that the heat-labile toxin (HLT) of B. bronchiseptica may be responsible for development of atrophic rhinitis in piglets. Live vaccine, using an isolant from a dog, was investigated first by Harris and Switzer (4) . In 1978, Shimizu (7) developed a new live vaccine, using strain ts-S34, which is temperature sensitive (ts).
Alcaligenes faecalis, nonpathogenic bacterium, is very similar to B. bronchiseptica in its biochemical characteristics, having only one known biochemical characteristic distinguishing it from B. bronchiseptica; it is urease negative (u-) (1) . We theorized that if strain ts-S34 could be induced to acquire the urease-negative property its usefulness would be increased. This paper deals with some characteristics of strain ts-S34 u-phase I of B. bronchiseptica, e.g., biochemical properties, colony growth rate, HLT production, antigenicity, and development of the immune state.
MATERIAIS AND METHODS
Guinea pigs. Male and female guinea pigs of the Hartley strain, weighing 300 to 350 g, were used in both HLT production and protection examinations. All guinea pigs were obtained from a breeding colony which had been proved to be free of B. bronchiseptica contamination by repeated examinations. The animals were placed in metal cages and fed commercial pellets and tap water ad libitum. Groups of animals receiving vaccine were kept in separate cages in the same isolation room.
Strains. Two cultures of B. bronchiseptica, S1 and A19, were used. These strains were isolated from natural cases of swine atrophic rhinitis in 1969 by Shimizu and maintained in a state of lyophilization.
Four additional strains, ts-S34, ts-S34'u-phase I (original and subculture of 20 passages), and ts-S34u-phase III, which had been derived from strain S1 or ts-S34 by exposure to mutagen(s), were used. Escherichia coli B41 (O:101,H:-,K:99) and A. faecalis IAM1473 were used as the control strains.
Exposure to mutagens and recovery of the ts-S34-umutant. Two mutagens, N-methyl-N'-nitro-N-nitrosoguanidine, and UV irradiation, were used jointly (7) . In this experiment, the survival rate of treated ts-S34 organisms was targeted at about 10-2. After treatment, the ts-S34 u-mutant was isolated by using the replicate plate method. However, the u-isolants were phase III organisms. Colony growth rate. Colony growth rates of phase I strains ts-S34 u-and S1 were measured by using both BG and TS media at 32°C.
HLT production. HLT production tests were performed by the method described by Nakase (6) Agglutinability of test strains against hyperimmune sera. The preparation of hyperimmune serum was according to Nakase's method (5) . Anti-SI hyperimmune rabbit serum and anti-ts-S34u-hyperimmune specific-pathogen-free pig serum were prepared. A modified agglutination method (8) with Formalin-killed antigens was applied to the sera.
Vaccine inoculation. Strain ts-S34u-phase I was used for vaccine preparation. The strain was cultured on BG medium at 32°C for 2 days; at harvest, cells were suspended homogeneously in 0.15 M phosphatebuffered saline, pH 7.0. Each 0.4 ml of freshly prepared bacterial suspension containing 1.5 x 109 organ- Challenge inoculation. The prophylactic value of the ts-S34u-vaccine was assessed by intranasal challenge inoculation with 1.32 x 10'°S1 organisms at week 4 after immunization (1,500 x the 50% lethal dose of this strain). Animals were observed for 5 weeks after challenge, after which survivors were killed and necropsied immediately. At necropsy, various organs were cultured for the challenge strain.
RESULTS
Urea hydrolysis is shown in Table 1 . No ts-S34-u-strains (including phase I original, phase I subculture of 20 passages, and phase III organisms) hydrolyzed urea through 7 days. Strains Si and A19 were positive at 2 h.
Four strains, Si, A19, ts-S34, and ts-S34u-phase III organism, grew in KCN broth after 2 days of incubation but strain ts-S34-u-phase I original and its subculture of 20 passages demonstrated greatly reduced growth at day 4 ( Table  2) .
Growth on Simmons citrate agar is shown in Table 3 . Strains Si and A19 grew after 1 day of It was confirmed that the reversion frequency related to u-or ts of strain ts-S34 u-phase I was lower than 10-9.8.
Colony growth rates of phase I strains ts-S34'u-and S1 at 32°C are shown in Fig. 1 . Even in the case of cultivating the organisms on TS medium, which is very suitable for propagating B. bronchiseptica, the incubation period required to obtain a colony 0.5 mm or more in diameter was 3 days for strain ts-S34u-, but only 1 day was required for strain S1.
A comparison of HLT titers offive test strains is shown in Table 4 . The HLT titer of strain ts-S34-u-was barely 1:2, but that of strain Si was 1:64.
The agglutinability of B. bronchiseptica antigens against hyperimmune sera, including Kitasato antigen, was 1:20,480 for all antigens, but that of an A. faecalis strain was <1:10 ( Table 5 ).
The effect of vaccination with live strain ts-S34-u-is shown in Table 6 . All 12 guinea pigs immunized with the vaccine survived without manifesting clinical symptoms for 5 weeks after challenge, but all 10 unvaccinated animals died with hemorrhagic pneumonia within 14 days after challenge. Challenge inocula were recovered in every nonvaccinated and vaccinated animal.
DISCUSSION
We had noticed before that a few small colo- nies would appear belatedly after strain ts-S34 phase I was cultured on ordinary agar medium over 3 days at 32°C. These small colonies grew to moderate size after further incubation for a few days and were hemolytic. In this experiment, we obtained strain ts-S34-u-phase I organism through strain ts-S34 u-phase III organism by repeated selection of the small forms. This phenomenon may indicate that both dissociation and reverse dissociation are variations and not mutations.
Strain ts-S34 u-phase I subculture of 20 passages did not hydrolyze urea. The in vitro reversion frequency related to the u-or ts property of strain ts-S34 u-was at least as low as 10-98. A revertant strain for either u-or ts was not isolated from any of the 12 guinea pigs inoculated with live ts-S34u-vaccine. These results suggest that strain ts-S34u-phase I has acquired the hereditarily stable u-and ts properties. Therefore, both u-and ts are useful hereditary markers for the live vaccine.
The colony growth rate of strain ts-S34u-phase I is slower than that of wild-type strain S1. (Table 4) . This property probably is advantageous for the vaccine strain.
All three strains of B. bronchiseptica showed the same level of agglutinability against both anti-Si and anti-ts-S34u-hyperimmune sera. These results suggest that strain ts-S34 u-has the same K antigen as that of strain S1. The agglutinability ofA. faecalis against both anti-B. bronchiseptica hyperimmune sera was lower than 1:10 even though A. faecalis is indistinguishable taxonomically from strain ts-S34 u-in its biochemical properties. This result shows that the antigenic structure of strain ts-S34 u-is quite different from that of A. faecalis.
The live ts-S34 u-phase I strain vaccination protected guinea pigs from challenge exposure with virulent strain S1. In the case of strain ts-S34 vaccination, a lesser protective effect had been shown with a challenge dose of 4,000 x the 50% lethal dose (7) .
It appears that strain ts-S34u-phase I has more favorable properties than strain ts-S34 for use as a live attenuated vaccine, i.e., from the standpoint of u-marker, HLT, and protection.
